<DOC>
	<DOC>NCT00084071</DOC>
	<brief_summary>The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.</brief_summary>
	<brief_title>Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Lipoprotein-associated coagulation inhibitor</mesh_term>
	<criteria>Diagnosis of communityacquired pneumonia supported by additional clinical, radiological, and microbiological evidence Pneumonia of sufficient severity to require ICU admission and management Pregnancy Weight over 150 kg Patients at increased risk of bleeding Treatment with drotrecogin alfa or anticipated need for drotrecogin alfa Treatment with heparin or anticipated need for heparin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>